Key result
Captopril demonstrates sustained effectiveness and therapeutic benefits in resistant hypertension and chronic congestive heart failure, with a benefit-to-risk ratio that justifies its use.
Why the study?
Does captopril improve outcomes in patients with resistant hypertension and congestive heart failure?
Does captopril improve outcomes in patients with resistant hypertension and congestive heart failure?
Captopril provides a favorable benefit-to-risk ratio for the treatment of resistant hypertension and congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Supports captopril consideration in resistant hypertension and HF; leaves open need for contemporary RCTs versus current standards.
Vlasses et al. (1982) conducted a review in Resistant hypertension and congestive heart failure. Captopril was evaluated. Captopril demonstrates sustained effectiveness and therapeutic benefits in resistant hypertension and chronic congestive heart failure, with a benefit-to-risk ratio that justifies its use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: